TW201304777A - 於一人口子集中治療非小細胞肺癌的方法 - Google Patents

於一人口子集中治療非小細胞肺癌的方法 Download PDF

Info

Publication number
TW201304777A
TW201304777A TW101113329A TW101113329A TW201304777A TW 201304777 A TW201304777 A TW 201304777A TW 101113329 A TW101113329 A TW 101113329A TW 101113329 A TW101113329 A TW 101113329A TW 201304777 A TW201304777 A TW 201304777A
Authority
TW
Taiwan
Prior art keywords
asian
motetanil
lung cancer
small cell
cell lung
Prior art date
Application number
TW101113329A
Other languages
English (en)
Chinese (zh)
Inventor
Yong-Jiang Hei
Bin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TW201304777A publication Critical patent/TW201304777A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW101113329A 2011-04-13 2012-04-13 於一人口子集中治療非小細胞肺癌的方法 TW201304777A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161475163P 2011-04-13 2011-04-13

Publications (1)

Publication Number Publication Date
TW201304777A true TW201304777A (zh) 2013-02-01

Family

ID=46018098

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101113329A TW201304777A (zh) 2011-04-13 2012-04-13 於一人口子集中治療非小細胞肺癌的方法

Country Status (7)

Country Link
JP (1) JP2014510793A (ko)
KR (1) KR20140022876A (ko)
CN (1) CN103764139A (ko)
AU (1) AU2012242773A1 (ko)
SG (1) SG194453A1 (ko)
TW (1) TW201304777A (ko)
WO (1) WO2012142325A1 (ko)

Also Published As

Publication number Publication date
SG194453A1 (en) 2013-12-30
CN103764139A (zh) 2014-04-30
WO2012142325A1 (en) 2012-10-18
KR20140022876A (ko) 2014-02-25
JP2014510793A (ja) 2014-05-01
AU2012242773A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
EP1915151B1 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
US20140243339A1 (en) Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
US20090030005A1 (en) Combinations for the treatment of cancer
US20110229469A1 (en) Methods for the treatment of cancer
TW201325589A (zh) 調節某些酪氨酸激酶
US8648199B2 (en) Process for making a solid-state form of AMG 706
US20140187526A1 (en) Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition
EP1987023B1 (en) Hydrate forms of amg706
US20140234328A1 (en) Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US20150336915A1 (en) Structures of proteasome inhibitors and methods for synthesizing and use thereof
WO2014028595A1 (en) Deuterated ponatinib
TW201304777A (zh) 於一人口子集中治療非小細胞肺癌的方法
WO2020223235A1 (en) Mini-tablet dosage forms of ponatinib
ES2367872T3 (es) Combinaciones para el tratamiento de cáncer que comprenden un anticuerpo anti-egfr e inhibidores de vegfr.